ATE256730T1 - Rekombinante mykobakterielle expressions-träger sowie deren verwendung - Google Patents

Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Info

Publication number
ATE256730T1
ATE256730T1 AT89908028T AT89908028T ATE256730T1 AT E256730 T1 ATE256730 T1 AT E256730T1 AT 89908028 T AT89908028 T AT 89908028T AT 89908028 T AT89908028 T AT 89908028T AT E256730 T1 ATE256730 T1 AT E256730T1
Authority
AT
Austria
Prior art keywords
mycobacteria
recombinant
mycobacterial
vector
coli
Prior art date
Application number
AT89908028T
Other languages
English (en)
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Robert N Husson
Original Assignee
Whitehead Biomedical Inst
Einstein Coll Med
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Einstein Coll Med, Univ Leland Stanford Junior filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE256730T1 publication Critical patent/ATE256730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89908028T 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung ATE256730T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21639088A 1988-07-07 1988-07-07
US22308988A 1988-07-22 1988-07-22
US07/361,944 US5504005A (en) 1987-03-02 1989-06-05 Recombinant mycobacterial vaccine
PCT/US1989/002962 WO1990000594A2 (en) 1988-07-07 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor

Publications (1)

Publication Number Publication Date
ATE256730T1 true ATE256730T1 (de) 2004-01-15

Family

ID=27396269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89908028T ATE256730T1 (de) 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Country Status (8)

Country Link
US (5) US5504005A (de)
EP (1) EP0424437B1 (de)
JP (2) JP3485916B2 (de)
AT (1) ATE256730T1 (de)
AU (1) AU3867789A (de)
CA (1) CA1339526C (de)
DE (1) DE68929507T2 (de)
WO (1) WO1990000594A2 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
EP0400973B1 (de) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
CA2063414A1 (en) * 1989-06-19 1990-12-20 Richard A. Young Vector-mediated genomic insertion and expression of dna in bcg
WO1991013157A1 (en) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
GB9015888D0 (en) * 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
AU643842B2 (en) * 1990-10-25 1993-11-25 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
WO1992007582A1 (en) * 1990-10-25 1992-05-14 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
AU2221992A (en) * 1991-06-06 1993-01-08 Med Immune, Inc. Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments
WO1992021376A1 (en) * 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
JPH06511145A (ja) * 1991-06-13 1994-12-15 アルバート　アインシュタイン　カレッジ　オブ　メディシン、ア　ディビジョン　オブ　イェシーバ　ユニバーシティ ミコバクテリア内での挿入突然変異
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (de) 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
US5750384A (en) * 1992-02-07 1998-05-12 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University L5 shuttle phasmids
US6300061B1 (en) 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
EP0700445B1 (de) * 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stressproteine und ihre verwendung
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
FR2720076B1 (fr) * 1994-05-20 1996-08-02 Inst Nat Sante Rech Med Vecteurs navettes pour l'introduction d'ADN dans des mycobactéries et utilisation de ces bactéries comme vaccins.
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP2001512435A (ja) * 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
CA2282426A1 (en) * 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
AU3710597A (en) 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
US6322991B1 (en) * 1997-08-21 2001-11-27 York University High-throughput screens for enzyme inhibitors
EP0902086A1 (de) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
US6387694B1 (en) * 1998-04-03 2002-05-14 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial isocitrate lyase gene and uses thereof
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US7022320B1 (en) * 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU5926700A (en) * 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
EP1229931A4 (de) * 1999-10-07 2003-05-28 Corixa Corp Fusionsproteine aus mycobacterium tuberculosis
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001051081A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6471967B1 (en) 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
PT2133100E (pt) * 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
KR100919266B1 (ko) 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
ATE357461T1 (de) 2000-08-25 2007-04-15 Aventis Pasteur Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
CN1484700A (zh) 2000-11-02 2004-03-24 �¼��¹�����ѧ aopB基因,蛋白,同系物,片段和它们的变体,以及它们在细胞表面展示方面的应用
US6921534B2 (en) * 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7758874B2 (en) * 2002-02-19 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated Mycobacterium tuberculosis vaccines
WO2003070164A2 (en) * 2002-02-19 2003-08-28 Albert Einstein College Of Medicine Of Yeshiva University Attenuated mycobacterium tuberculosis vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
CN100572540C (zh) * 2002-04-16 2009-12-23 成都永安制药有限公司 包括表达丙氨酸脱氢酶、丝氨酸脱水酶和/或谷氨酰胺合成酶的重组卡介苗菌株的结核病疫苗
DE60319822T2 (de) * 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
WO2004016280A1 (ja) * 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えｂｃｇワクチン
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US8084041B2 (en) * 2003-01-24 2011-12-27 Albert Einstein College Of Medicine Of Yeshiva University Use of mycrobacterial vaccines in CD4+ or CD8+ lymphocyte-deficient mammals
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
EP1684798A4 (de) * 2003-10-16 2007-12-05 Univ California Rekombinante intrazelluläre pathogen-immunogene zusammensetzungen und anwendungsverfahren
WO2007121194A1 (en) * 2006-04-10 2007-10-25 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
WO2007121193A1 (en) * 2006-04-10 2007-10-25 The Regents Of The University Of California Growth regulatable recombinant bcg immunogenic compositions
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
AU2006204907B2 (en) * 2005-01-12 2011-08-11 Albert Einstein College Of Medicine, Inc. Mycobacterial mutants affecting host apoptosis
US7998471B2 (en) * 2005-01-12 2011-08-16 Albert Einstein College Of Medicine Of Yeshiva University Mycobacteria expressing HIV-1 and malaria antigens
AU2006206851B2 (en) 2005-01-18 2010-12-16 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
JP2009502747A (ja) * 2005-07-14 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア １−メチル−ピラゾール−４−イルカルボキシアニリド類に基づく殺菌性混合物
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
US8168421B2 (en) * 2005-12-09 2012-05-01 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
US8101191B2 (en) * 2006-01-12 2012-01-24 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial SecA2 mutants
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
WO2009008912A2 (en) 2007-03-19 2009-01-15 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants inducing il-12
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
RU2392002C2 (ru) * 2008-04-02 2010-06-20 ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова Способ получения туберкулезного анатоксина
RU2372936C1 (ru) * 2008-05-19 2009-11-20 Закрытое акционерное общество "Томские клеточные технологии" (ЗАО "Томские клеточные технологии") Способ получения аутологичной вакцины для лечения туберкулеза
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
US9717781B2 (en) 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
US9447449B2 (en) 2011-10-21 2016-09-20 Albert Einstein College Of Medicine, Inc. Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
US20150211012A1 (en) 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
DK178233B1 (en) 2012-09-17 2015-09-14 Novartis Tiergesundheit Ag Fiskevaccine
WO2014070975A1 (en) 2012-11-02 2014-05-08 Novartis Ag Flavivirus associated with theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
RU2016128557A (ru) 2013-12-29 2018-02-01 Кьюрлаб Онколоджи, Инк. МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
CA3045756A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
PL3964529T3 (pl) 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
US10774391B2 (en) * 2016-03-31 2020-09-15 University Of The Witwatersrand, Johannesburg Genetically modified strains of mycobacterium smegmatis
JP2019520075A (ja) * 2016-06-30 2019-07-18 テクノロジー イノベーション モメンタム ファンド（イスラエル）リミテッド パートナーシップＴｅｃｈｎｏｌｏｇｙ Ｉｎｎｏｖａｔｉｏｎ Ｍｏｍｅｎｔｕｍ Ｆｕｎｄ（ｉｓｒａｅｌ）Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ 広範囲の宿主範囲を有するバクテリオファージバリアント、核酸を目的の宿主に形質導入する際のその調製方法及び用途
EP3596202A4 (de) 2017-03-14 2021-01-27 The Regents of the University of California Genomweite identifizierung von immunevasionsfunktionen in einem virus
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
EP4317441A4 (de) * 2021-03-22 2025-09-17 Clipsbnc Co Ltd Neuer rekombinanter stamm von mycobacterium smegmatis und verwendung davon
WO2023034804A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59205983A (ja) * 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
US4743546A (en) * 1985-02-13 1988-05-10 Biotechnica International, Inc. Controlled gene excision
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
US5968733A (en) 1999-10-19
JP3485916B2 (ja) 2004-01-13
WO1990000594A3 (en) 1990-05-03
US6270776B1 (en) 2001-08-07
DE68929507D1 (de) 2004-01-29
US5504005A (en) 1996-04-02
EP0424437A1 (de) 1991-05-02
AU3867789A (en) 1990-02-05
CA1339526C (en) 1997-11-04
WO1990000594A2 (en) 1990-01-25
JP2000350578A (ja) 2000-12-19
EP0424437B1 (de) 2003-12-17
JPH04500305A (ja) 1992-01-23
DE68929507T2 (de) 2004-09-23
US6372478B1 (en) 2002-04-16
US5854055A (en) 1998-12-29

Similar Documents

Publication Publication Date Title
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
KR940010865B1 (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
EP0856059B1 (de) Verfahren zur herstellung von rekombinanten plasmiden
AU5848090A (en) Vector-mediated genomic insertion and expression of dna in bcg
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
DE3854840D1 (de) Rekombinant-mykobakterielle impfstoffe
ATE214100T1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
AU3041295A (en) Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
EP1363660A4 (de) "überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation"
IL133056A (en) Polypeptide containing an immunogenic portion of an m. tuberculosis antigen, a variant thereof and pharmaceutical compositions containing same
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
JP2001514000A5 (de)
IE821428L (en) Foot and mouth disease vaccine
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
KR970703165A (ko) 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections)
Haeseleer et al. Stable integration and expression of the Plasmodium falciparum circumsporozoite protein coding sequence in mycobacteria
AU2387892A (en) Nucleotide sequences and resistance proteins cycloheximide
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
AU5776799A (en) Modified hcv peptide vaccines
CA2446260A1 (en) Novel expression vectors and uses thereof
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
KR920006503A (ko) 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties